Bildkälla: Stockfoto

InDex Pharmaceuticals: CMD Key Takeaways - Redeye

Redeye leaves a comment on InDex Pharmaceuticals following its Capital Markets Day, where the company announced it estimates a 2027 launch of Cobitolimod and gave updates on its ambitions of commercial path.

Redeye leaves a comment on InDex Pharmaceuticals following its Capital Markets Day, where the company announced it estimates a 2027 launch of Cobitolimod and gave updates on its ambitions of commercial path.
Börsvärldens nyhetsbrev
ANNONSER